Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.

Thuret I, Chaix ML, Tamalet C, Reliquet V, Firtion G, Tricoire J, Rabaud C, Frange P, Aumaître H, Blanche S.

AIDS. 2009 Nov 13;23(17):2364-6. doi: 10.1097/QAD.0b013e328331a456.

PMID:
19823069
[PubMed - indexed for MEDLINE]
2.

Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.

Vento S, Vallone A.

AIDS Patient Care STDS. 2008 Nov;22(11):841-2. doi: 10.1089/apc.2008.0051. No abstract available.

PMID:
19025477
[PubMed - indexed for MEDLINE]
3.

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D, Molina JM, Chêne G; ANRS 139 TRIO Trial Group.

Clin Infect Dis. 2009 Nov 1;49(9):1441-9. doi: 10.1086/630210.

PMID:
19814627
[PubMed - indexed for MEDLINE]
Free Article
4.

Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.

Boffito M, Winston A, Jackson A, Fletcher C, Pozniak A, Nelson M, Moyle G, Tolowinska I, Hoetelmans R, Miralles D, Gazzard B.

AIDS. 2007 Jul 11;21(11):1449-55.

PMID:
17589191
[PubMed - indexed for MEDLINE]
5.

Follow-up of a multi-drug resistant HIV-1 infected patient successfully treated with darunavir and etravirine.

Audelin AM, Lebech AM, Petersen AB, Jørgensen LB.

J Med Virol. 2008 Aug;80(8):1319-21. doi: 10.1002/jmv.21226.

PMID:
18551616
[PubMed - indexed for MEDLINE]
6.

Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.

Nakamura H, Miyazaki N, Hosoya N, Koga M, Odawara T, Kikuchi T, Koibuchi T, Kawana-Tachikawa A, Fujii T, Miura T, Iwamoto A.

J Infect Chemother. 2011 Feb;17(1):105-10. doi: 10.1007/s10156-010-0082-4. Epub 2010 Jun 30.

PMID:
20585968
[PubMed - indexed for MEDLINE]
7.

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.

Charpentier C, Roquebert B, Colin C, Taburet AM, Fagard C, Katlama C, Molina JM, Jacomet C, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D; ANRS 139 TRIO Trial study group.

AIDS. 2010 Nov 13;24(17):2651-6. doi: 10.1097/QAD.0b013e32833ed2a7.

PMID:
20802293
[PubMed - indexed for MEDLINE]
8.

Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).

Charpentier C, Fagard C, Colin C, Katlama C, Molina JM, Jacomet C, Visseaux B, Taburet AM, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D; ANRS139 TRIO Trial study group.

PLoS One. 2013;8(1):e53621. doi: 10.1371/journal.pone.0053621. Epub 2013 Jan 17.

PMID:
23349724
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.

Jaworsky D, Thompson C, Yudin MH, Bitnun A, Brophy J, Samson L, Antoniou T, Loutfy MR.

Antivir Ther. 2010;15(4):677-80. doi: 10.3851/IMP1558.

PMID:
20587860
[PubMed - indexed for MEDLINE]
10.

Etravirine: new drug. Multidrug-resistant HIV: another option.

[No authors listed]

Prescrire Int. 2009 Jun;18(101):102-3.

PMID:
19637414
[PubMed - indexed for MEDLINE]
11.

Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.

Do VT, Higginson RT, Fulco PP.

Am J Health Syst Pharm. 2011 Nov 1;68(21):2049-54. doi: 10.2146/ajhp110083.

PMID:
22011983
[PubMed - indexed for MEDLINE]
12.

Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.

[No authors listed]

Prescrire Int. 2008 Aug;17(96):135-7.

PMID:
19480091
[PubMed - indexed for MEDLINE]
14.

Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.

Codoñer FM, Pou C, Thielen A, García F, Delgado R, Dalmau D, Álvarez-Tejado M, Ruiz L, Clotet B, Paredes R.

PLoS One. 2011;6(5):e19461. doi: 10.1371/journal.pone.0019461. Epub 2011 May 13.

PMID:
21602929
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

Imaz A, del Saz SV, Ribas MA, Curran A, Caballero E, Falcó V, Crespo M, Ocaña I, Diaz M, de Gopegui ER, Riera M, Ribera E.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):382-6. doi: 10.1097/QAI.0b013e3181b17f53. Erratum in: J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):e102.

PMID:
19654552
[PubMed - indexed for MEDLINE]
16.

Raltegravir and etravirine are active against HIV type 1 group O.

Briz V, Garrido C, Poveda E, Morello J, Barreiro P, de Mendoza C, Soriano V.

AIDS Res Hum Retroviruses. 2009 Feb;25(2):225-7. doi: 10.1089/aid.2008.0222.

PMID:
19239363
[PubMed - indexed for MEDLINE]
17.

HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.

Florence E, De Wit S, Castagna A, Ribera E, Hill A, Vanaken H, van Delft Y, Marks S.

Int J STD AIDS. 2010 Mar;21(3):224-5. doi: 10.1258/ijsa.2009.009425. Epub 2010 Jan 13. No abstract available.

PMID:
20071441
[PubMed - indexed for MEDLINE]
18.

[Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].

Arazo Garcés P, Omiste Sanvicente T.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 10:23-31. Review. Spanish.

PMID:
19195456
[PubMed - indexed for MEDLINE]
19.

Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.

Caby F, Valin N, Marcelin AG, Schneider L, Andrade R, Guiguet M, Tubiana R, Canestri A, Valantin MA, Peytavin G, Pacanowski J, Morand-Joubert L, Calvez V, Girard PM, Katlama C.

Scand J Infect Dis. 2010 Jul;42(6-7):527-32. doi: 10.3109/00365541003621502.

PMID:
20222846
[PubMed - indexed for MEDLINE]
20.

Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.

Towner W, Lalezari J, Sension MG, Wohlfeiler M, Gathe J, Appelbaum JS, Bellman P, Gottlieb MS, Ryan R, Nijs S, Hoogstoel A, Van Solingen-Ristea R, Witek J.

J Acquir Immune Defic Syndr. 2010 Apr;53(5):614-8. doi: 10.1097/QAI.0b013e3181cdebb1.

PMID:
20134329
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk